178 related articles for article (PubMed ID: 32175831)
1. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
Cao S; Dong YH; Wang DF; Liu ZP
Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
[TBL] [Abstract][Full Text] [Related]
2. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
3. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
4. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
5. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
6. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
8. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
9. Marine Derived Anticancer Drugs Targeting Microtubule.
De O; Chatterji BP
Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173
[TBL] [Abstract][Full Text] [Related]
10. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
11. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
13. Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop.
Abel AC; Mühlethaler T; Dessin C; Schachtsiek T; Sammet B; Sharpe T; Steinmetz MO; Sewald N; Prota AE
J Biol Chem; 2024 May; 300(6):107363. PubMed ID: 38735475
[TBL] [Abstract][Full Text] [Related]
14. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials.
Kumar B; Kumar R; Skvortsova I; Kumar V
Curr Cancer Drug Targets; 2017; 17(4):357-375. PubMed ID: 27697026
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
17. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
[TBL] [Abstract][Full Text] [Related]
18. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.
Hamblett KJ; Jacob AP; Gurgel JL; Tometsko ME; Rock BM; Patel SK; Milburn RR; Siu S; Ragan SP; Rock DA; Borths CJ; O'Neill JW; Chang WS; Weidner MF; Bio MM; Quon KC; Fanslow WC
Cancer Res; 2015 Dec; 75(24):5329-40. PubMed ID: 26631267
[TBL] [Abstract][Full Text] [Related]
19. Microtubule-targeting agents and their impact on cancer treatment.
Čermák V; Dostál V; Jelínek M; Libusová L; Kovář J; Rösel D; Brábek J
Eur J Cell Biol; 2020 May; 99(4):151075. PubMed ID: 32414588
[TBL] [Abstract][Full Text] [Related]
20. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]